Ral Therapy. AIDS Res Ther 2010, 7:three. doi:ten.1186/1742-6405-7-3. 40. Fox-Rushby JA

Ral Therapy. AIDS Res Ther 2010, 7:three. doi:ten.1186/1742-6405-7-3. 40. Fox-Rushby JA, Hanson K: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness evaluation. Health Policy Program 2001, 16:32631. 41. Ortblad KF, Lozano R, Murray CJ: The burden of HIV: insights from the GBD 2010. AIDS (London, England) 2013. 42. GDP per capits (existing US ). http://data.worldbank.org/indicator/NY.GDP. PCAP.CD.43. Kashuba AD, Abdool Karim SS, Kraft E, White N, Sibeko S, Werner L, Mansoor LE, Gengiah T, Sidhoo S, Abdool Karim Q: Do systemic and genital tract tenofovir concentrations predict HIV seroconversion inside the CAPRISA 004 tenofovir gel trial In XVIII International AIDS Conference 183 July. Vienna, Austria; 2010. 44. Watts CH, Kumaranayake L, Vickerman P, Terris-Prestholt F: The public wellness effect of microbicides: model projections.DLPC Data Sheet Report in the Public Well being Added benefits Working Group. In the Rockefeller Foundation Microbicide Initiative. 2002. http://www.global-campaign.org/clientfiles/rep7_publichealth.pdf. 45. Watts C, Vickerman P: The effect of microbicides on HIV and STD transmission: model projections. AIDS 2000, 15:S43 44. 46. Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G: The cost-effectiveness of herpes simplex virus-2 suppressive therapy with each day aciclovir for delaying HIV illness progression amongst HIV-1-infected women in South Africa.LY294002 Technical Information Sex Transm Dis 2011, 38:40109.PMID:23937941 47. Terris-Prestholt F, Kumaranayake L, MacPhail C, Rees H, Watts C: Determinants of South African Women’s Demand for New Barrier Solutions and their Distribution: Evaluation of a Discrete Option Experiment. In IAEN; 1 August; Cuernavaca; 2008. 48. Foss AM, Vickerman PT, Heise L, Watts CH: Shifts in condom use following microbicide introduction: need to we be concerned AIDS 2003, 17:1227237. 49. Williams BG, Karim SSA, Karim QA, Gouws E: Epidemiological effect of tenofovir gel around the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011, 58:20710. 50. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR 3rd, Paltiel AD: The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012, 54:1504513. 51. Verguet S, Walsh JA: Vaginal microbicides save income: a model of cost-effectiveness in South Africa and also the USA. Sex Transm Infect 2010, 86:21216. 52. MDP Statement around the Discontinuation of Tenofovir gel within the VOICE Trial. http://www.mdp.mrc.ac.uk/. 53. Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, Watya S, Reynolds SJ, Wawer M: The impact of male circumcision on HIV incidence and expense per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 2007, 21:84550. 54. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP: Understanding the effect of male circumcision interventions on the spread of HIV in southern Africa. PLoS A single 2008, three:e2212. 55. White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA, Kumaranayake L, Habbema JD, Buve A, Hayes RJ: Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when AIDS 2008, 22:1841850. 56. Cox AP, Foss AM, Vickerman PT, Chimbwete C, Okonji E, Terris-Prestholt F, Beksinska M, Walaza S, von Mollendorf C, Smit J, et al: Producing realistic impact projections for new HIV prevention technologies: searching beyond a product’s efficacy. In 18th International Society for Sexually Transmitted Illnesses Research; 28 June – 1 July. London, UK;.